TREAT注册研究13年期间报告的妊娠结局:一项描述性报告
基于TREAT注册研究(1999-2012年),分析克罗恩病(CD)患者妊娠结局;妊娠期或孕前暴露于英夫利西单抗及未暴露于生物制剂者,母方和父方结局中活产健康婴儿比例均较高,妊娠期暴露组母方自然流产率数值上更高,但该组CD更重且更常用免疫抑制剂。
要点
- 母方妊娠在妊娠期、孕前及非生物制剂暴露组的健康婴儿活产率分别为92.6%、91.2%、87.8%。
- 母方妊娠新生儿并发症率在妊娠期、孕前及非生物制剂暴露组分别为6.2%、7.0%、8.5%。
- 妊娠期英夫利西单抗暴露女性所生婴儿临床状况与未暴露者相似,但活产率较低。
核心结论
- 妊娠期英夫利西单抗暴露女性所生婴儿的临床状况与未暴露者相似。
- 英夫利西单抗暴露女性活产率较低,但这些患者CD更严重且更可能暴露于免疫抑制剂。
研究设计与样本
- TREAT注册研究(1999-2012年)的描述性报告,分析母方和父方患者妊娠结局。
- 暴露分组:妊娠期暴露(妊娠结局前≤365天使用英夫利西单抗)、孕前暴露(>365天)及非生物制剂暴露。
主要发现
- 总体92.3%(324/351)的妊娠有已知结局。
- 母方妊娠健康婴儿活产率:妊娠期暴露组92.6%、孕前暴露组91.2%、非生物制剂暴露组87.8%。
- 父方结局健康婴儿活产率:妊娠期暴露组92.7%、孕前暴露组93.8%、非生物制剂暴露组91.7%。
- 母方妊娠新生儿并发症率:妊娠期暴露组6.2%、孕前暴露组7.0%、非生物制剂暴露组8.5%。
- 父方结局新生儿并发症率:妊娠期暴露组4.9%、孕前暴露组0%、非生物制剂暴露组0%。
关键数值与推荐
- 健康婴儿定义为无先天异常、无新生儿并发症(如黄疸、早产、心脏杂音、皮质视觉/精细运动延迟、心力衰竭、血友病或斜颈)、无延长住院或未接受特殊治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We described pregnancy outcomes in Crohn's disease (CD) patients enrolled in the TREAT Registry who received infliximab before, or during pregnancy and those not treated with infliximab or any biologic agent. METHODS: In the TREAT Registry (1999-2012), pregnancy outcomes were analyzed from maternal and paternal patients exposed to infliximab ≤365 days (gestational exposure), >365 days (pre-gestational exposure) of pregnancy outcome or without infliximab exposure (non-biologic exposed). "Healthy infants" were defined as those with no congenital abnormalities, neonatal complications (e.g., jaundice, prematurity, heart murmur, cortical vision/fine motor delay, cardiac failure, hemophilia, or torticollis), prolonged hospitalization, or those who received no special treatment. Disease activity and concomitant medications were also evaluated. RESULTS: Overall, 92.3% (324/351) of pregnancies had known outcomes. The majority of both maternal pregnancies (92.6, 91.2, and 87.8%) and partner outcomes (92.7, 93.8, and 91.7%) resulted in live births of healthy infants across gestational, pre-gestational, and non-biologic exposure groups, respectively. Among these, rates of neonatal complications were low for both maternal (6.2, 7.0, and 8.5%), and partner outcomes (4.9, 0, and 0%) in gestational, pre-gestational, and non-biologic exposure groups, respectively. Among maternal pregnancies, numerically higher rates of spontaneous abortions were observed for the gestational exposure group than for the pre-gestational or non-biologic exposed groups. CONCLUSIONS: The clinical condition of infants born to women with gestational infliximab exposure was similar to those without exposure. Although a lower live birth rate was reported among infliximab-exposed women, these patients had more severe CD and were more likely to have been exposed to immunosuppressives.
引用
- Lichtenstein GR, Feagan BG, Mahadevan U, et al. Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. Am J Gastroenterol. 2018. PMID: 30022113. doi:10.1038/s41395-018-0202-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。